At 10.8% CAGR, the South & Central America Stem Cell Therapy Market is projected to be worth US$ 139.30 million by 2028, says Business Market Insights

According to Business Market Insights research, the South & Central America stem cell therapy market was valued at US$ 75.16 million in 2022 and is expected to reach US$ 139.30 million by 2028, registering a CAGR of 10.8% from 2022 to 2028. Increasing research activities related to stem cell therapy for effective disease management and use of induced pluripotent stem cells in regenerative medicines are the critical factors attributed to the South & Central America stem cell therapy market expansion.               

Stem cell therapy has been widely investigated across the world. Stem cells are mainly used to replace dying cells and reconstruct damaged tissues. Based on the results of extensive stem cell research conducted so far, many scientists have claimed that these cells could probably be utilized to generate cures and treatments for diseases such as cancer and cardiovascular disease. Newly developed stem cell therapies involve replacing disease-causing cells with stem cells. Many potential treatments involving stem cells are in different phases of clinical trials. Researchers are further investigating the use of stem cell therapy in treating autoimmune disorders. For example, stem cells can turn into the cells of damaged organs and are used in treating autoimmune diseases. Treatment is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic stem cells are currently used for treating more than 80 medicals conditions, including immune system diseases, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and cancer types such as leukemia and lymphoma.  

On the contrary, high cost of approved treatments hurdles the growth of South & Central America stem cell therapy market.

Based on type, the South & Central America stem cell therapy is segmented into adult stem cell therapy, embryonic stem cell therapy, induced pluripotent stem cell therapy, and other stem cell therapy. The adult stem cell therapy segment held 60.0% share of South & Central America stem cell therapy market in 2022, amassing US$ 45.09 million. It is projected to garner US$ 85.25 million by 2028 to expand at 11.2% CAGR during 2022–2028. The adult stem cell therapy segment is further segmented into hematopoietic stem cell therapy, umbilical cord stem cell therapy, neuronal stem cell therapy, and mesenchymal stem cell.

Based on treatment, the South & Central America stem cell therapy is bifurcated into allogeneic and autologous. The allogeneic segment held 55.9% share of South & Central America stem cell therapy market in 2022, amassing US$ 42.05 million. It is projected to garner US$ 76.85 million by 2028 to expand at 10.6% CAGR during 2022–2028.

Based on application, the South & Central America stem cell therapy is segmented into musculoskeletal, dermatology, cardiology, drug discovery & development, and other applications. The musculoskeletal segment held 33.2% share of South & Central America stem cell therapy market in 2022, amassing US$ 24.92 million. It is projected to garner US$ 45.59 million by 2028 to expand at 10.6% CAGR during 2022–2028.

Based on end user, the South & Central America stem cell therapy is bifurcated into hospitals & specialty clinics and academic & research institutes. The academic & research institutes segment held 53.5% share of South & Central America stem cell therapy market in 2022, amassing US$ 40.24 million. It is projected to garner US$ 75.60 million by 2028 to expand at 11.1% CAGR during 2022–2028.

Based on country, the South & Central America stem cell therapy is segmented into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 44.2% share of South & Central America stem cell therapy market in 2022. It was assessed at US$ 33.26 million in 2022 and is likely to hit US$ 64.03 million by 2028, exhibiting a CAGR of 11.5% during 2022–2028.

Key players profiled in the South & Central America stem cell therapy market report Lonza Group AG, Pluri Inc, Smith & Nephew Plc, and TiGenix NV (Takeda Pharmaceutical Company Limited), among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com